Tuesday, July 2, 2013
Halozyme Therapeutics Inc., of San Diego, reported interim results from a proof-of-concept Phase I/II trial evaluating the activity and local tolerability of HTI-501, an investigational biologic, for use in aesthetic dermatology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.